RT Journal Article
T1 SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).
A1 Majem, M
A1 Juan, O
A1 Insa, A
A1 Reguart, N
A1 Trigo, J M
A1 Carcereny, E
A1 García-Campelo, R
A1 García, Y
A1 Guirado, M
A1 Provencio, M
K1 Chemotherapy
K1 Immunotherapy
K1 NSCLC
K1 Radiotherapy
K1 Targeted therapies
AB Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment attains greater value.
YR 2018
FD 2018-11-17
LK http://hdl.handle.net/10668/13197
UL http://hdl.handle.net/10668/13197
LA en
DS RISalud
RD Apr 7, 2025